Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.
Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Fujii H, et al. Among authors: ishikawa h. World J Hepatol. 2015 Dec 8;7(28):2841-8. doi: 10.4254/wjh.v7.i28.2841. World J Hepatol. 2015. PMID: 26668696 Free PMC article.
Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis.
Takahashi A, Moriguchi M, Seko Y, Shima T, Mitsumoto Y, Takashima H, Kimura H, Fujii H, Ishikawa H, Takaharu Y, Ishiba H, Morita A, Jo M, Nagao Y, Arai M, Hara T, Okajima A, Muramatsu A, Yoshinami N, Nakajima T, Mitsuyoshi H, Umemura A, Nishikawa T, Yamaguchi K, Okanoue T, Itoh Y. Takahashi A, et al. Among authors: ishikawa h. Cancers (Basel). 2020 Mar 23;12(3):754. doi: 10.3390/cancers12030754. Cancers (Basel). 2020. PMID: 32209994 Free PMC article.
Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A, Moriguchi M, Seko Y, Ishikawa H, Yo T, Kimura H, Fujii H, Shima T, Mitsumoto Y, Ishiba H, Takashima H, Nagao Y, Jo M, Arai M, Hara T, Okajima A, Muramatsu A, Morita A, Yoshinami N, Nakajima T, Mitsuyoshi H, Umemura A, Nishikawa T, Yamaguchi K, Itoh Y. Takahashi A, et al. Among authors: ishikawa h. Anticancer Res. 2019 Sep;39(9):5149-5156. doi: 10.21873/anticanres.13710. Anticancer Res. 2019. PMID: 31519627
Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B.
Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M. Kobashi H, et al. Among authors: ishikawa h. Hepatol Int. 2009 Jun;3(2):403-10. doi: 10.1007/s12072-008-9108-8. Epub 2008 Dec 9. Hepatol Int. 2009. PMID: 19669367 Free PMC article.
Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial.
Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, Okanoue T, Tsubouchi H, Ishikawa H, Seriu T, Omata M. Shindo M, et al. Among authors: ishikawa h. Hepatol Int. 2009 Sep;3(3):445-52. doi: 10.1007/s12072-009-9135-0. Epub 2009 May 23. Hepatol Int. 2009. PMID: 19669249 Free PMC article.
4,494 results